1.820USD-2.15%Mkt Cap: 26.36M USDP/E: —Last update: 2026-05-26
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of pero…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap26.36M USD
Enterprise Value26.68M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.26M USD
Revenue/Share—
Last Price1.820 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.50
PEG—
EV/EBITDA-1.01
EV/Revenue—
P/S—
P/B1.34
EPS (TTM)-5.70
EPS (Forward)-1.21
52W Range
1.5003% of range12.23
52W High12.23 USD
52W Low1.500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-393.85%
ROA-155.11%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.82M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-66.72%
Net Debt434.00K USD
Net Debt/EBITDA-0.02
Balance Sheet
Debt/Equity1.22
Current Ratio2.50
Quick Ratio2.33
Book Value/Sh1.353 USD
Cash/Share0.5370 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 10, 2018
Splits
Last Split1:13
Split DateApr 9, 2025
Analyst Consensus
Rating—
Target (Mean)11.00 USD
Target Range11.00 USD – 11.00 USD
# Analysts1
Ownership
Shares Out.14.81M
Float9.27M
Insiders34.26%
Institutions28.49%
Short Interest
Short Ratio1.4d
Short % Float6.85%
Short % Out.2.75%
Shares Short395.02K
Short (prev mo.)449.00K
Technical
SMA 501.905 (-4.5%)
SMA 2005.235 (-65.2%)
Beta-1.69
S&P 52W Chg28.31%
Avg Vol (30d)172.39K
Avg Vol (10d)115.26K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—